Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act
Idag, 16:00
Company Announcement, Helsinki, 18 May 2026 at 5 PM (EEST)
Nexstim Plc ("Nexstim" or "Company") has received a notification pursuant to chapter 9, section 5 of the Securities Market Act on 15 May 2026. According to the notification, Eiffel Investment Group’s holdings of the shares and votes in Nexstim exceeds 5% as of 13 May 2026.
Total position of Eiffel Investment Group according to the notification:
% of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in %
(7.A + 7.B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 8.93 % | 8.93 % | 8,074,859 | |
Positions of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | |
FI4000506811 | 327,438 | 4.12 % | ||
FI4000506811 | 138,156 | 1.74 % | ||
FI4000506811 | 119,118 | 1.50 % | ||
FI4000506811 | 118,180 | 1.49 % | ||
FI4000506811 | 6,658 | 0.08 % | ||
SUBTOTAL A | 709,550 | 8.93 % |
Information in relation to the entity subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held:
Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of shares, voting rights, and financial instruments |
FCPI ALTO INNOVATION 2022 | 4.12 % | 327,438 | |
FCPI ALTO INNOVATION 2024 | 1.74 % | 138,156 | |
FCPI ALTO INNOVATION 2023 | 1.50 % | 119,118 | |
FCPI EIFFEL INNOVATION STRATEGIQUE | 1.49 % | 118,180 | |
FCPR EIFFEL ENTREPRENEURS | 0.08 % | 6,658 |
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.
AttachmentsCompany announcement_Liputusilmoitus_18052026_EN_FINAL.pdf
Ämnen i artikeln
Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act
Idag, 16:00
Company Announcement, Helsinki, 18 May 2026 at 5 PM (EEST)
Nexstim Plc ("Nexstim" or "Company") has received a notification pursuant to chapter 9, section 5 of the Securities Market Act on 15 May 2026. According to the notification, Eiffel Investment Group’s holdings of the shares and votes in Nexstim exceeds 5% as of 13 May 2026.
Total position of Eiffel Investment Group according to the notification:
% of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in %
(7.A + 7.B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 8.93 % | 8.93 % | 8,074,859 | |
Positions of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | |
FI4000506811 | 327,438 | 4.12 % | ||
FI4000506811 | 138,156 | 1.74 % | ||
FI4000506811 | 119,118 | 1.50 % | ||
FI4000506811 | 118,180 | 1.49 % | ||
FI4000506811 | 6,658 | 0.08 % | ||
SUBTOTAL A | 709,550 | 8.93 % |
Information in relation to the entity subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held:
Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of shares, voting rights, and financial instruments |
FCPI ALTO INNOVATION 2022 | 4.12 % | 327,438 | |
FCPI ALTO INNOVATION 2024 | 1.74 % | 138,156 | |
FCPI ALTO INNOVATION 2023 | 1.50 % | 119,118 | |
FCPI EIFFEL INNOVATION STRATEGIQUE | 1.49 % | 118,180 | |
FCPR EIFFEL ENTREPRENEURS | 0.08 % | 6,658 |
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.
AttachmentsCompany announcement_Liputusilmoitus_18052026_EN_FINAL.pdf
Ämnen i artikeln
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
